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Radiotherapy (RT) is a standard therapeutic strategy in
the treatment in head and neck cancer (HNC), but many
patients still experience recurrence and metastasis. Inter-
estingly, radiotherapy (RT) may also induce immunomo-
dulatory effects. Given the recent, exciting responses seen
using anti-PD-1 (programmed death-1) checkpoint block-
ade immunotherapy in recurrent/metastatic disease,
including HNC, we evaluated the combination of RT with
anti-PD-1 therapy in a pre-clinical mouse model of locally
advanced, untreated HPV-positive HNC. We compared
utilizing PD-1 blockade before, during or after RT, as well
as whether a single large faction (12Gy) or multiple smal-
ler RT doses (2 Gy X 10 fractions) confers optimal antitu-
mor immune responses and tumor shrinkage. We
observed that fractionated doses of RT induced the highest
PD-L1 (programmed death-ligand 1) expression on HNC
cells in vitro and in treated mice. A loading dose of anti-
PD-1 mAb therapy prior to RT appeared to be important
for best therapeutic outcome, with greatest tumor
response and tumor-specific immunity using PD-1 Ab
loading dose than sequential administration of anti-PD-1
mAb after fractionated RT (p < 0.0001). Expression and
intensity of PD-1 receptor expression on circulating
T cells differentially impacted the T cell phenotype and
anti-tumor outcome, with loss of PD-1(high) exhausted
T cells during the best tumor response (p < 0.05). The
combination of fractionated RT + anti-PD-1 Ab optimally
upregulated the frequency of HPV E7 tumor antigen-
specific T cells (p < 0.05). This study may facilitate stra-
tegies required for the combination of RT and immune
checkpoint inhibitor in clinical trials, enabling more
effective clinical activity and biomarker evaluation.
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